| 24-May-13 01:51PM | Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Lead Plaintiff Deadline in Securities Class Action Against Ventrus Biosciences, Inc. -- VTUS GlobeNewswire |
| 22-May-13 06:43PM | Scott+Scott, Attorneys at Law, LLP Reminds Ventrus Biosciences, Inc. Investors of Upcoming Deadline in Securities Class Action Lawsuit -- VTUS GlobeNewswire |
| 21-May-13 04:49PM | SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Ventrus Biosciences, Inc. and Certain Officers -- VTUS GlobeNewswire |
| 18-May-13 09:00AM | Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Ventrus Biosciences, Inc. To Contact The Firm PR Newswire |
| 17-May-13 08:59PM | Ventrus Biosciences, Inc. Sued by Investor PR Newswire |
| 01:04PM | VENTRUS BIOSCIENCES INC Financials EDGAR Online Financials |
| 15-May-13 01:27PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventrus Biosciences, Inc. - VTUS PR Newswire |
| 13-May-13 05:33PM | SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $300,000 From Investment in Ventrus Biosciences, Inc. to Contact Brower Piven Before the July 8, 2013 Lead Plaintiff Deadline -- VTUS GlobeNewswire |
| 11:45AM | SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Ventrus Biosciences, Inc. of Class Action Lawsuit and the Deadline of July 8, 2013 to Seek a Lead Plaintiff Position -- VTUS GlobeNewswire |
| 12-May-13 12:16AM | Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Ventrus Bioscences, Inc. (NASDAQ: VTUS) Marketwired |
| 12:16AM | Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Ventrus Bioscences, Inc. (NASDAQ: VTUS) Marketwire |
| 10-May-13 04:05PM | Bronstein, Gewirtz & Grossman, LLC Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc. PR Newswire |
| 03:51PM | Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc. PR Newswire |
| 09:08AM | VENTRUS BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 09-May-13 10:20PM | VENTRUS BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ventrus Biosciences, Inc. - VT Marketwired |
| 10:20PM | VENTRUS BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ventrus Biosciences, Inc. - VT Marketwire |
| 01:43PM | Scott+Scott, Attorneys at Law, LLP Files Securities Class Action Lawsuit Against Ventrus Biosciences, Inc. -- VTUS GlobeNewswire |
| 09-Apr-13 09:24AM | VENTRUS BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 08-Apr-13 09:30AM | Zeldes & Haeggquist, LLP Announces Investigation of Ventrus Biosciences, Inc. Business Wire |
| 21-Mar-13 01:04PM | VENTRUS BIOSCIENCES INC Financials EDGAR Online Financials |
| 17-Mar-13 11:12PM | VENTRUS BIOSCIENCES INC Files SEC form 10-K, Annual Report EDGAR Online |
| 01-Mar-13 08:00AM | Ventrus Biosciences Announces Poster Presentation on the Quality of Compounded Topical Diltiazem Hydrochloride Formulations for Anal Fissure at the American Pharmacists Association Meeting GlobeNewswire |
| 22-Feb-13 12:39PM | 5 Stocks Ready to Break Out at TheStreet +8.92% |
| 12-Feb-13 10:49AM | Holzer Holzer & Fistel, LLC Announces Investigation into Ventrus Biosciences, Inc. Business Wire |
| 11-Feb-13 02:57PM | Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference GlobeNewswire |
| 07-Feb-13 05:20PM | VENTRUS BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 09:13AM | Ventrus Biosciences Announces Full Exercise of Overallotment Option by Underwriters GlobeNewswire |
| 04-Feb-13 05:01PM | VENTRUS BIOSCIENCES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Ev EDGAR Online |
| 31-Jan-13 08:20AM | Biotech Companies Attractive Targets for Pharmaceutical Companies Looking to Replace Lost Revenues Marketwired |
| 08:20AM | Biotech Companies Attractive Targets for Pharmaceutical Companies Looking to Replace Lost Revenues Marketwire |
| 30-Jan-13 04:19PM | VENTRUS BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State EDGAR Online -22.87% |
| 08:59AM | InPlay: Ventrus Biosciences prices public offcering of 5.8 mln shares of its common stock at $2.50 per share and 220,000 shares of its Series A Non-Voting Convertible Preferred Stock at $25.00 per share Briefing.com |
| 08:56AM | Ventrus Biosciences Announces $20 Million Financing GlobeNewswire |
| 29-Jan-13 04:53PM | 4 Healthcare Stock Stories for Tuesday Wellness at Wall St. Cheat Sheet +20.15% |
| 04:20PM | InPlay: Ventrus Biosciences announces proposed public offerings of common stock and Series A Convertible Preferred Stock; sizes of offerings not disclosed Briefing.com |
| 04:19PM | Ventrus Biosciences Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock GlobeNewswire |
| 10:44AM | InPlay: Ventrus Biosciences seeing continued strength (+19% today, +53% past two trading days) Briefing.com |
| 22-Jan-13 04:10PM | VENTRUS BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 07-Jan-13 11:02AM | VENTRUS BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 18-Dec-12 01:27PM | What No One Is Saying About Paramount Biosciences: 3 Case Histories And 4 Companies To Avoid at Seeking Alpha |
| 20-Nov-12 01:04PM | VENTRUS BIOSCIENCES INC Financials EDGAR Online Financials |
| 14-Nov-12 03:30PM | Apple Analyst Targets $750 Stock Price and 4 Insights Making Rounds at Wall St. Cheat Sheet |
| 02:04PM | Apple Analyst Targets $750 Stock Price and 4 Insights Making Rounds at Wall St. Cheat Sheet |
| 01:03PM | Apple Analyst Sees $750 Ahead and 4 Analyst Insights Making Rounds at Wall St. Cheat Sheet |
| 10:14AM | Apple Analyst Sees $750 Ahead and 4 Analyst Insights Making Rounds at Wall St. Cheat Sheet |
| 13-Nov-12 01:05PM | VENTRUS BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -7.21% |
| 12:31PM | Ventrus Biosciences Reports Third Quarter 2012 Financial Results GlobeNewswire |
| 11:24AM | VENTRUS BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 08-Nov-12 04:14PM | Ventrus Biosciences to Present at the Lazard Capital Markets 9th Annual Healthcare Conference GlobeNewswire -5.30% |
| 07-Nov-12 01:48PM | Pengrowth Energy Board Approves Commitment and 1 Stock Hitting 52-Week Lows at Wall St. Cheat Sheet |
| 08:19AM | Pengrowth Energy Board Approves Commitment and 1 Stock Hitting 52-Week Lows at Wall St. Cheat Sheet |
| 06-Nov-12 06:21PM | Affymetrix Estimates Lowered and 4 Stock Analyses to Eye at Wall St. Cheat Sheet |
| 10:03AM | Affymetrix Estimates Lowered and 4 Stock Analyses to Eye at Wall St. Cheat Sheet |
| 05-Nov-12 09:52AM | VENTRUS BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -7.49% |
| 09:46AM | PropThink: FDA Confirms Necessity of Ventrus' Second Phase III Thomson Reuters ONE |
| 07:33AM | InPlay: Ventrus Biosciences receives FDA written feedback, targets NDA filing for Diltiazem (VEN 307) in anal fissures following second Phase 3 study Briefing.com |
| 07:30AM | Ventrus Biosciences Receives FDA Written Feedback, Targets NDA Filing for Diltiazem (VEN 307) in Anal Fissures Following Second Phase 3 Study GlobeNewswire |
| 03-Oct-12 09:01AM | PropThink: With a Late-Stage GI Asset and Quality Financials, VTUS Has Room for Growth Thomson Reuters ONE |
| 28-Sep-12 08:53AM | PropThink: VEN-307 is Ideal for a Small Company to Launch, says Ventrus CEO Thomson Reuters ONE |
| 24-Sep-12 07:30AM | Ventrus Biosciences Appoints JP Benya Vice President, Commercial Operations and Business Development GlobeNewswire |
| 21-Sep-12 04:23PM | VENTRUS BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events EDGAR Online |
| 05-Sep-12 04:09PM | VENTRUS BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online +6.30% |
| 03:15PM | 4 Stocks Under $10 Making Big Moves at TheStreet |
| 29-Aug-12 07:00AM | Ventrus Biosciences to Present at Upcoming Investor Conferences in September GlobeNewswire |
| 17-Aug-12 01:05PM | VENTRUS BIOSCIENCES INC Financials EDGAR Online Financials |
| 13-Aug-12 10:10AM | Equity Briefing: Upgrades and Downgrades for August 10th: AEO, ALXA, HMIN, JDSU, LMCA, NVDA, TJX, VTUS Thomson Reuters ONE |
| 10-Aug-12 10:45AM | VTUS An Oversold Opportunity; Now May Be The Time To Buy Thomson Reuters ONE |
| 06:14AM | Ventrus Biosciences upgraded by Cantor Fitzgerald Briefing.com |
| 09-Aug-12 05:10PM | Ventrus Biosciences Reports Second Quarter 2012 Financial Results GlobeNewswire |
| 05:01PM | VENTRUS BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 10-Jul-12 04:55AM | 3 new bets by a biotech hedge fund at MarketWatch -5.10% |
| 04:55AM | 3 new bets by a biotech hedge fund at MarketWatch |
| 06-Jul-12 05:33PM | Walter Energy, Ventrus Biosciences Among Stocks hitting 52-Week Lows Friday at Fox Business |
| 05:12PM | Walter Energy, Ventrus Biosciences Among Stocks hitting 52-Week Lows Friday at Fox Business |
| 29-Jun-12 06:00AM | The Five Dumbest Things on Wall Street This Week: June 29 at TheStreet |
| 05:00AM | [video] The 5 Dumbest Things on Wall Street, June 29 at TheStreet |
| 28-Jun-12 09:08AM | 4 Reasons To Buy Ventrus Biosciences - Update at Seeking Alpha |
| 27-Jun-12 01:36PM | Quality Systems, Natural Resource Partners Among Stocks setting 52-Week Lows Wednesday at Fox Business |
| 12:56PM | Quality Systems, Natural Resource Partners Among Stocks setting 52-Week Lows Wednesday at Fox Business |
| 26-Jun-12 06:03PM | Nasdaq stocks posting largest percentage decreases AP -5.18% |
| 01:19PM | Nasdaq stocks posting largest percentage decreases AP |
| 10:40AM | Garmin NAVIGATES Ahead of Expectations and 4 Equity Insights to Watch at Wall St. Cheat Sheet |
| 25-Jun-12 06:56PM | Healthcare Biz Recap: FDA PROBES Pfizers New Drug, Ventrus Biosciences ABANDONS Treatment at Wall St. Cheat Sheet -59.05% |
| 06:04PM | Nasdaq stocks posting largest percentage decreases AP |
| 05:15PM | Healthcare Business Recap: FDA PROBES Pfizers New Drug, Ventrus Biosciences ABANDONS Treatment at Wall St. Cheat Sheet |
| 01:59PM | Ventrus implodes on drug study at MarketWatch |
| 01:54PM | Wall St. Equity Downgrades to Evaluate Now at Wall St. Cheat Sheet |
| 01:20PM | Ventrus Biosciences plunges on study failure AP |
| 01:19PM | Nasdaq stocks posting largest percentage decreases AP |
| 11:58AM | Mondays biggest gaining and declining stocks at MarketWatch |
| 11:40AM | 2 Riskier Companies I'm Considering Selling In The Short Term, And Buying In The Long Term at Seeking Alpha |
| 10:21AM | Ventrus Biosciences IMPLODES 58% and 4 Stocks with Horrible News Now at Wall St. Cheat Sheet |
| 08:44AM | Mondays biggest gaining and declining stocks at MarketWatch |
| 08:22AM | Ventrus drops piles drug after late-stage failure at Reuters |
| 07:09AM | Ventrus has no immediate plans to continue development of VEN 309 theflyonthewall.com |
| 07:01AM | InPlay: Ventrus Biosciences provides results from pivotal Phase 3 trial of Iferanserin in patients with hemorrhoidal diseasel; says 'Results of this large, well-controlled study failed to demonstrate an improvement for therapy' Briefing.com |
| 07:00AM | Ventrus Biosciences Announces Results From Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease GlobeNewswire |
| 20-Jun-12 10:29AM | On The Fly: Analyst Initiation Summary theflyonthewall.com +5.13% |
| 19-Jun-12 10:23AM | On The Fly: Analyst Initiation Summary theflyonthewall.com -5.67% |
| 14-Jun-12 02:08PM | Ventrus Biosciences rises on analyst comments AP +8.07% |
